Global Human Platelet Lysate Market Is Estimated To Witness High Growth Owing To Growing Awareness Regarding Blood Donation And Rising Research And Development Of Human Platelet Lysate For Treating Traumatic Brain Injury

Human Platelet Lysate Market

Overview:

Platelets play a central role not only in primary hemostasis but also in the process of tissue repair and regeneration. Human platelet lysate (HPL) contains an abundant repertoire of growth factors and cytokines, supporting cell proliferation in the absence of Fetal Bovine Serum (FBS). In cell culture, human platelet lysate is used as a xeno-free alternative to Fetal Bovine Serum (FBS). The growth-promoting effects of hPL are attributed to its high content of soluble proteins and cytokines. It is a potent reagent for the ex-vivo expansion of human adherent and non-adherent cell types including mesenchymal stem cells (MSCs). hPL is also known to increase the proliferation rate of cells in comparison to FBS-based media. These factors are expected to fuel the Human Platelet Lysate Market during the forecast period.

 

Global Human Platelet Lysate Market is estimated to be valued at US$ 53.0 million in 2023 and is expected to exhibit a CAGR of 4.54% during the forecast period (2023-2030).

 

Market Dynamics:

The rising adoption of inorganic growth strategies by key players is estimated to augment the growth of the global market during the forecast period. For instance, a clinical-stage biopharmaceutical company Calidi Bio Therapeutics and Edoc Acquisition Corp, declared their merger in February 2022. They are aiming to create a clinical-stage biotechnology company using stem cell-based platforms for revolutionizing oncolytic virotherapy. Moreover, the increasing cost of human platelet lysate products is anticipated to restrain the growth of the global Human Platelet Lysate Market during the forecast period.

 

Impact of COVID-19:

The pandemic was first reported in 2019in China. It affected the global economy as trade activities were temporarily halted during that period. The pandemic also had a significant impact on the growth of several markets globally. Manufacturers had to halt production activities owing to strict restrictions imposed by governments in many countries. Several research activities were being conducted to develop vaccines, drugs, or treatments against COVID-19 in many countries. This led to an increase in demand for human platelet lysate. Thus, the global Human Platelet Lysate Market witnessed growth during the pandemic.

 

Key Takeaways:

The global Human Platelet Lysate Market is expected to witness robust growth, exhibiting CAGR of 4.54 % over the forecast period, due to increasing research and developmental activities. For instance, a biotechnological center CiRA Foundation, which is focusing on CGT Catapult and cell research launched a new research project in May 2020. This project aims to induce pluripotent stem cell characterization.

 

North America is anticipated to witness robust growth in the global Human Platelet Lysate Market during the forecast period, due to growing favorable support from regulatory authorities and rising research and development activities. The global Parkinson’s Disease Therapeutic Market is estimated to be valued at US$ 4,697.3 million in 2021 and is expected to exhibit a CAGR of 6.3% during the forecast period (2021-2028).

Key players active in the global Human Platelet Lysate Market are Thermo Fisher Scientific, e STEMCELL Technologies Inc., Regenexx, Merck KGaA, BBI Solutions, Mill Creek Life Sciences, Life Science Group Ltd., Merck & Co., Inc., Cook Regentec, AventaCell BioMedical, PL BioScience GmbH, Compass Biomedical, Inc, and Macopharma SA.